Quoin Pharmaceuticals Stock Surges 30% After Alliance Global Partners Set Buy Rating

Shares of Quoin Pharmaceuticals, Ltd. (QNRX) are surging over 30% on Wednesday morning after analysts at Alliance Global Partners set a "buy" rating on the stock.

QNRX is currently trading at $4.3700, up $1.0500 or 31.6265%, on the Nasdaq, on a volume of 32 million shares, far above average volume of 1.8 million. The stock opened its trading at $3.96 after closing Tuesday's trading at $3.32. The stock has traded between $2.9400 and $372.5000 in the past 52-week range.

Quoin Pharmaceuticals, a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT